Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.

Immunotherapeutic and monitoring of tacrolimus in recipients of liver transplantation

The Use of Tacrolimus in 932 Renal Transplant Recipients

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

A Clinical Research of Taerolimus (prograf) in the Prevention of Renal Allograft Rejection:A Report of 136 Cases

The Comparison of Two Immunosuppression Schemes Containing Tacrolimus in Renal Transplant Recipients

Anti-acute Rejection Regime with Tacrolimus in Renal Transplantation Patients

Application of Tacrolimus in 862 Renal Transplantation Recipients

Long-term Evaluation of FK506 Based Immunosuppressive Therapy in Kidney Transplantation

Administration of Tacrolimus in 50 Liver Transplantation Patients.

A Meta-Analysis of Therapeutic Effect of Cyclosporine Microemulsion and Tacrolimus for Patients Undergoing Liver Transplantation

Comparison of the efficacy of low-dosage versus standard-dosage tacrolimus after kidney transplantation by programming renal biopsies

Clinical Study on the Use of FK506 after Renal Transplantation

Analysis of T Lymphocyte Subgroups and CD28-family Co-Stimulators in Allo-Liver Recipients Receiving Tacrolimus Treatment

A Retrospective Analysis of the Safety and Efficacy of Low Dose Tacrolimus (fk506) for Living Donor Liver Transplant Recipients

A Pilot Clinical Study of Tacrolimus(fk506) in Cadavaric Renal Transplant Recipients with Delayed Graft Function and Early Acute Rejection

Tacrolimus Alleviates Acute Liver Graft Rejection by Inhibiting Glucocorticoid-Induced Tumor Necrosis Factor-Related Protein Ligand in Rats

Clinical Pharmacokinetics of Tacrolimus in Heart Transplantation Recipients

Effectiveness and Safety of Tacrolimus Dual Regimen Versu Triple Regimen for Patients after Liver Transplantation: A Meta-analysis

Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation

The Prospective Randomized Study on Prevention of Cadaveric Renal Allograft Rejection by Tacrolimus (FK506)

Effect of Low-Dose Tacrolimus with Mycophenolate Mofetil on Renal Function Following Liver Transplantation.